Amarin reported $48.15M in Trade Creditors for its fiscal quarter ending in March of 2026.





Trade Creditors Change Date
AbbVie USD 3.59B 28.65B Dec/2025
Alnylam Pharmaceuticals USD 126.63M 10.91M Mar/2026
Amarin USD 48.15M 2.8M Mar/2026
AstraZeneca USD 22.51B 2.78B Mar/2026
BioCryst Pharmaceuticals USD 10.96M 4.87M Mar/2026
DBV Technologies USD 39.82M 972K Sep/2025
Esperion Therapeutics USD 68.41M 3.34M Mar/2026
GlaxoSmithKline GBP 14.34B 1.05B Mar/2026
Halozyme Therapeutics USD 14.1M 6.8M Mar/2026
Heron Therapeutics USD 8.97M 24K Mar/2026
Ionis Pharmaceuticals USD 26.03M 2.05M Mar/2026
Nektar Therapeutics USD 10.77M 4.79M Dec/2025
Neurocrine Biosciences USD 691.3M 145.8M Mar/2026
Novartis USD 4.32B 134M Mar/2026